Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Geniculate Artery Embolization for Recurrent Effusion After Total Knee Arthroplasty in a Patient With Hemophilia.

Cureus·2026
Same author

Emergency mitral valve transcatheter edge-to-edge repair in cardiogenic shock due to papillary muscle rupture.

Journal of cardiology cases·2026
Same author

Stem Cell and Cell-Free Strategies for Osteoarthritis: Toward Durable Regenerative Therapies.

Stem cells international·2026
Same author

Artificial intelligence in breaking the learning curve for echocardiography: a secondary analysis of a multicentre trial.

European heart journal. Digital health·2026
Same author

Control of cell division by an <i>Acinetobacter baumannii</i> protein with a novel nucleotidyl-cyclase-like fold.

bioRxiv : the preprint server for biology·2026
Same author

A view-flexible deep learning framework for automated analysis of 2D echocardiography.

NPJ cardiovascular health·2026

Related Experiment Video

Updated: Jul 16, 2026

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles
09:01

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles

Published on: September 27, 2013

Enhanced angiogenesis with multimodal cell-based gene therapy.

Terrence M Yau1, Christopher Kim, Guangming Li

  • 1Division of Cardiovascular Surgery, Toronto General Hospital, Ontario, Canada. terry.yau@uhn.on.ca

The Annals of Thoracic Surgery
|February 20, 2007
PubMed
Summary

Transient overexpression of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) synergized angiogenesis after bone marrow cell (BMC) transplantation. This multimodal gene therapy improved heart function but did not fully normalize it.

More Related Videos

Visualizing Angiogenesis by Multiphoton Microscopy In Vivo in Genetically Modified 3D-PLGA/nHAp Scaffold for Calvarial Critical Bone Defect Repair
09:34

Visualizing Angiogenesis by Multiphoton Microscopy In Vivo in Genetically Modified 3D-PLGA/nHAp Scaffold for Calvarial Critical Bone Defect Repair

Published on: September 7, 2017

Adenoviral Gene Therapy for Diabetic Keratopathy: Effects on Wound Healing and Stem Cell Marker Expression in Human Organ-cultured Corneas and Limbal Epithelial Cells
11:13

Adenoviral Gene Therapy for Diabetic Keratopathy: Effects on Wound Healing and Stem Cell Marker Expression in Human Organ-cultured Corneas and Limbal Epithelial Cells

Published on: April 7, 2016

Related Experiment Videos

Last Updated: Jul 16, 2026

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles
09:01

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles

Published on: September 27, 2013

Visualizing Angiogenesis by Multiphoton Microscopy In Vivo in Genetically Modified 3D-PLGA/nHAp Scaffold for Calvarial Critical Bone Defect Repair
09:34

Visualizing Angiogenesis by Multiphoton Microscopy In Vivo in Genetically Modified 3D-PLGA/nHAp Scaffold for Calvarial Critical Bone Defect Repair

Published on: September 7, 2017

Adenoviral Gene Therapy for Diabetic Keratopathy: Effects on Wound Healing and Stem Cell Marker Expression in Human Organ-cultured Corneas and Limbal Epithelial Cells
11:13

Adenoviral Gene Therapy for Diabetic Keratopathy: Effects on Wound Healing and Stem Cell Marker Expression in Human Organ-cultured Corneas and Limbal Epithelial Cells

Published on: April 7, 2016

Area of Science:

  • Regenerative Medicine
  • Cardiovascular Research
  • Gene Therapy

Background:

  • Myocardial repair remains a challenge after cardiac injury.
  • Cell-based therapies offer potential for cardiac regeneration.
  • Optimizing gene therapy vectors for cell transplantation is crucial.

Purpose of the Study:

  • To evaluate the synergistic effects of transient vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) overexpression.
  • To assess the impact of multimodal gene therapy on angiogenesis and left ventricular (LV) function post-bone marrow cell (BMC) transplantation.
  • To determine the potential of this approach for myocardial repair.

Main Methods:

  • Lewis rats underwent coronary ligation followed by transplantation of BMCs, BMCs with VEGF, BMCs with bFGF, or BMCs with both VEGF and bFGF.
  • Transgene expression, angiogenesis (vascular density), LV function (ejection fraction), and regional perfusion were quantified at various time points post-transplantation.

Main Results:

  • VEGF and bFGF were transiently expressed over 4 weeks.
  • Combined VEGF and bFGF overexpression in BMCs significantly enhanced angiogenesis and LV ejection fraction compared to controls.
  • While improved, perfusion and function were not fully normalized.

Conclusions:

  • Transient co-expression of VEGF and bFGF demonstrates powerful synergism in promoting angiogenesis post-cell transplantation.
  • Multimodal cell-based gene therapy shows promise for myocardial repair.
  • Future strategies may involve combining this approach with other novel therapies.